{
    "clinical_study": {
        "@rank": "18322", 
        "acronym": "STRATEGIC-1", 
        "arm_group": [
            {
                "arm_group_label": "STRATEGY A", 
                "arm_group_type": "Experimental", 
                "description": "FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab"
            }, 
            {
                "arm_group_label": "STRATEGY B", 
                "arm_group_type": "Experimental", 
                "description": "OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan"
            }
        ], 
        "brief_summary": {
            "textblock": "STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with\n      metastatic colorectal cancer."
        }, 
        "brief_title": "Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer Metastatic", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase III study assessing 2 mutli-line therapeutic strategies in patients with\n      unresectable wild-type RAS metastatic colorectal cancer. All the available treatments are\n      being used in each strategy (oxaliplatine, irinotecan, fluoropyrimidines, bevacizumab,\n      cetuximab or panitumumab) but in a different order:\n\n      STRATEGY A: FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab\n      vs.\n\n      STRATEGY B: OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab,\n      followed by anti-EGFR mab with or without irinotecan."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed and dated informed consent, and willing and able to comply with protocol\n             requirements,\n\n          2. Histologically proven adenocarcinoma of the colon and/or rectum,\n\n          3. Wild-type RAS tumor no mutation in exon 2 [codon 12/13], exon 3 [codon 59/61] and\n             exon 4 [codon 117/146] of both KRAS and NRAS genes (local assessment, performed\n             either on primary tumor or metastasis),\n\n          4. Metastatic disease confirmed,\n\n          5. No prior therapy for metastatic disease (in case of previous adjuvant therapy,\n             interval from end of chemotherapy and relapse must be >6 months for fluoropyrimidine\n             alone or >12 months for oxaliplatin-based, bevacizumab-based, or cetuximab-based\n             therapy),\n\n          6. Duly documented unresectable metastatic disease, ie not suitable for complete\n             carcinological surgical resection at inclusion [NB: patients with unresectable\n             disease at study entry but with any potential of salvage surgery after induction\n             therapy are eligible],\n\n          7. At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic\n             Resonance Imaging) according to RECIST v1.1,\n\n          8. Age \u226518 years,\n\n          9. ECOG Performance status (PS) 0-2,\n\n         10. Hematological status: neutrophils (ANC) \u22651.5x109/L; platelets \u2265100x109/L; haemoglobin\n             \u22659g/dL,\n\n         11. Adequate renal function: serum creatinine level <150\u00b5M,\n\n         12. Adequate liver function: serum bilirubin  \u22641.5 x upper normal limit (ULN), alkaline\n             phosphatase <5xULN,\n\n         13. Proteinuria <2+ (dipstick urinalysis) or \u22641g/24hour,\n\n         14. Baseline evaluations performed before randomization when the KRAS WT status is known:\n             clinical and blood evaluations no more than 2 weeks (14 days) prior to randomization,\n             tumor assessment (CT-scan or MRI, evaluation of non-measurable lesions) no more than\n             3 weeks (21 days) prior to randomization,\n\n         15. Female patients must commit to using reliable and appropriate methods of\n             contraception during the trial and until at least six months after the end of study\n             treatment (when applicable). Male patients with a partner of childbearing potential\n             must agree to use contraception in addition to having their partner use another\n             contraceptive method during the trial and until at least 6 months after the end of\n             the study treatment,\n\n         16. Registration in a national health care system (CMU included for France).\n\n        Exclusion Criteria:\n\n          1. History or evidence upon physical examination of CNS metastasis (e.g. non irradiated\n             CNS metastasis, seizure not controlled with standard medical therapy), unless\n             adequately treated,\n\n          2. Exclusive bone metastasis,\n\n          3. Uncontrolled hypercalcemia,\n\n          4. Pre-existing permanent neuropathy (NCI grade \u22652),\n\n          5. Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or\n             diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or\n             hypertensive encephalopathy,\n\n          6. Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted\n             therapy, immunotherapy),\n\n          7. Treatment with any investigational medicinal product within 28 days prior to study\n             entry,\n\n          8. Other serious and uncontrolled non-malignant disease,\n\n          9. Gilbert's syndrome,\n\n         10. Other concomitant or previous malignancy, except: i/ adequately treated in-situ\n             carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin,\n             iii/ cancer in complete remission for >5 years,\n\n         11. Major surgery (open biopsy, surgical resection, wound revision or any other major\n             surgery involving entry into body cavity) or significant traumatic injury within the\n             last 28 days prior to randomization, and/or minor surgical procedure including\n             placement of a vascular device within 2 days of first study treatment,\n\n         12. Pregnant or breastfeeding women,\n\n         13. Patients with known allergy/hypersensitivity to any component of study drugs,\n\n         14. History of arterial thrombo and/or embolic event (e.g. myocardial infarction,\n             stroke,\u2026) within 6 months prior to randomization,\n\n         15. Chronic inflammatory bowel disease\n\n         16. Total bowel obstruction,\n\n         17. History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI\n             bleeding within 6 months prior to randomization,\n\n         18. Serious, non-healing wound, active ulcer or untreated bone fracture,\n\n         19. History or evidence of inherited bleeding diathesis or significant coagulopathy at\n             risk of bleeding,\n\n         20. Current or recent (within 10 days of randomization) use of aspirin (>325 mg/d),\n             clopidogrel (>75 mg/d) or use of oral anticoagulants or thrombolytic agents.\n\n         21. Concomitant administration of live, attenuated virus vaccine such as yellow fever\n             vaccine\n\n         22. Concomitant administration of prophylactic phenytoin.\n\n         23. Treatment with sorivudine or its chemically related analogues, such as brivudine.\n\n         24. Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.\n\n         25. Concomitant use with St John's Wort\n\n         26. Patients with interstitial pneumonitis or pulmonary fibrosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "474", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910610", 
            "org_study_id": "STRATEGIC-1 C12- 2", 
            "secondary_id": "2013-001928-19"
        }, 
        "intervention": [
            {
                "arm_group_label": "STRATEGY A", 
                "intervention_name": "FOLFIRI-cetuximab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "STRATEGY A", 
                "intervention_name": "mFOLFOX6-bevacizumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "STRATEGY B", 
                "intervention_name": "OPTIMOX-bevacizumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "STRATEGY B", 
                "intervention_name": "irinotecan-based chemo + bevacizumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "STRATEGY B", 
                "intervention_name": "Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "STRATEGY A", 
                    "STRATEGY B"
                ], 
                "intervention_name": "XELOX + bevacizumab", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Irinotecan", 
                "Bevacizumab", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "wild-type RAS metastatic colorectal cancer", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Aur\u00e9lie PARZY, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France"
                    }, 
                    "name": "Centre Fran\u00e7ois Baclesse"
                }, 
                "investigator": {
                    "last_name": "Aur\u00e9lie PARZY, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Laurence SAUDES, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cannes", 
                        "country": "France", 
                        "zip": "06400"
                    }, 
                    "name": "Centre Hospitalier"
                }, 
                "investigator": {
                    "last_name": "Laurence SAUDES, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Pascal HAMMEL, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Clichy", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Beaujon"
                }, 
                "investigator": {
                    "last_name": "Pascal HAMMEL, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gilles BREYSACHER, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Colmar", 
                        "country": "France"
                    }, 
                    "name": "Hospices Civils de Colmar"
                }, 
                "investigator": {
                    "last_name": "Gilles BREYSACHER, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christophe TOURNIGAND, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cr\u00e9teil", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Henri Mondor"
                }, 
                "investigator": {
                    "last_name": "Christophe TOURNIGAND, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Laurence GAUTHIER-FELIZOT, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Dax", 
                        "country": "France", 
                        "zip": "40107"
                    }, 
                    "name": "Centre Hospitalier"
                }, 
                "investigator": {
                    "last_name": "Laurence GAUTHIER-FELIZOT, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Fran\u00e7ois GHIRINGHELLI, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France"
                    }, 
                    "name": "Centre Georges Fran\u00e7ois Leclerc"
                }, 
                "investigator": {
                    "last_name": "Fran\u00e7ois GHIRINGHELLI, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roger FAROUX, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "La Roche sur Yon", 
                        "country": "France"
                    }, 
                    "name": "CHD Vend\u00e9e"
                }, 
                "investigator": {
                    "last_name": "Roger FAROUX, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gabriela TOSSEN, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Le Coudray", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Saint-Louis"
                }, 
                "investigator": {
                    "last_name": "Gabriela TOSSEN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Olivier DUPUIS, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Le Mans", 
                        "country": "France"
                    }, 
                    "name": "Clinique Victor Hugo"
                }, 
                "investigator": {
                    "last_name": "Olivier DUPUIS, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jo\u00eblle EGRETEAU, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lorient", 
                        "country": "France"
                    }, 
                    "name": "Centre Hospitalier de Bretagne Sud"
                }, 
                "investigator": {
                    "last_name": "Jo\u00eblle EGRETEAU, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "J\u00e9r\u00f4me DESRAME, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Priv\u00e9 Jean Mermoz"
                }, 
                "investigator": {
                    "last_name": "J\u00e9r\u00f4me DESRAME, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mohamed GASMI, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Nord"
                }, 
                "investigator": {
                    "last_name": "Mohamed GASMI, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yves RINALDI, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Ambroise Par\u00e9"
                }, 
                "investigator": {
                    "last_name": "Yves RINALDI, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "J\u00e9r\u00f4me DAUBA, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Mont de Marsan", 
                        "country": "France"
                    }, 
                    "name": "Centre Hospitalier Layn\u00e9"
                }, 
                "investigator": {
                    "last_name": "J\u00e9r\u00f4me DAUBA, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Fabien BROCARD, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Nancy", 
                        "country": "France"
                    }, 
                    "name": "Centre d'oncologie de Gentilly"
                }, 
                "investigator": {
                    "last_name": "Fabien BROCARD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jean-Fran\u00e7ois RAMEE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France"
                    }, 
                    "name": "Centre Sainte Catherine de Sienne"
                }, 
                "investigator": {
                    "last_name": "Jean-Fran\u00e7ois RAMEE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ga\u00ebl DEPLANQUE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Saint-Joseph"
                }, 
                "investigator": {
                    "last_name": "Ga\u00ebl DEPLANQUE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ahmed KHALIL, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Tenon"
                }, 
                "investigator": {
                    "last_name": "Ahmed KHALIL, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jean-Marc GORNET, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Saint-Louis"
                }, 
                "investigator": {
                    "last_name": "Jean-Marc GORNET, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Benoist CHIBAUDEL, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Saint-Antoine"
                }, 
                "investigator": {
                    "last_name": "Benoist CHIBAUDEL, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jean-Baptiste BACHET, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re"
                }, 
                "investigator": {
                    "last_name": "Jean-Baptiste BACHET, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christophe LOUVET, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Institut Mutualiste Montsouris"
                }, 
                "investigator": {
                    "last_name": "Christophe LOUVET, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Pierre-Luc ETIENNE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint-Brieuc", 
                        "country": "France"
                    }, 
                    "name": "Clinique Armoricaine de Radiologie"
                }, 
                "investigator": {
                    "last_name": "Pierre-Luc ETIENNE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dr Elisabeth CAROLA, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Senlis", 
                        "country": "France"
                    }, 
                    "name": "CH de Senlis"
                }, 
                "investigator": {
                    "last_name": "Elisabeth CAROLA, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Louis Marie DOURTHE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France"
                    }, 
                    "name": "Clinique Sainte-Anne"
                }, 
                "investigator": {
                    "last_name": "Louis-Marie DOURTHE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thonon Les Bains", 
                        "country": "France", 
                        "zip": "74200"
                    }, 
                    "name": "H\u00f4pitaux du L\u00e9man"
                }, 
                "investigator": {
                    "last_name": "Ahmed BEDJAOUI, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cyril BONAVENTURE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Valence", 
                        "country": "France"
                    }, 
                    "name": "Clinique G\u00e9n\u00e9rale"
                }, 
                "investigator": {
                    "last_name": "Cyril BONAVENTURE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villenueve d'Asq", 
                        "country": "France", 
                        "zip": "59657"
                    }, 
                    "name": "Institut de Canc\u00e9rologie"
                }, 
                "investigator": {
                    "last_name": "Olivier ROMANO, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.", 
        "overall_contact": {
            "last_name": "Benoist Chibaudel, MD", 
            "phone": "+33 (0)1 49 28 23 45"
        }, 
        "overall_official": {
            "affiliation": "H\u00f4pital Saint Antoine", 
            "last_name": "Benoist Chibaudel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: ANSM - French Competent Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Duration of Disease Control", 
            "safety_issue": "No", 
            "time_frame": "From baseline until end of strategy, assessed up to 80 months after the beginning of the study"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910610"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "QoL will be considered to be improved if at least one time to QoL score deterioration (Five targeted dimensions) will be significantly longer without a significant shorter time to QoL score dimensions for other 4 targeted dimensions.", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "from baseline until end of strategy, assessed up to 80 months after the beginning of the study"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "time interval from randomization to the date of death from any cause. Assessed up to 80 months after the beginning of the study."
            }, 
            {
                "description": "TFS is defined as beginning with the initiation of the strategy under investigation and ending with the first of the following events: 1) death, 2) disease progression on the last received planned sequence, 3) patient requires the addition of a new (unplanned) therapeutic agent, 4) patient experiences disease progression during a partial or complete break in therapy from initial treatment strategy and receives no further therapy within one month.", 
                "measure": "Time to Failure of Strategy", 
                "safety_issue": "No", 
                "time_frame": "Assessed up to 80 months after the beginning of the study"
            }, 
            {
                "measure": "Progression-free survival (PFS) per sequence of therapy", 
                "safety_issue": "No", 
                "time_frame": "the time interval from randomization to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed up to 80 months after the beginning of the study"
            }, 
            {
                "measure": "Tumor Response Rate (RR)", 
                "safety_issue": "No", 
                "time_frame": "from baseline until end of strategy, assessed up to 80 months after the beginning of the study"
            }, 
            {
                "measure": "Curative salvage surgery rate", 
                "safety_issue": "No", 
                "time_frame": "from baseline until end of strategy, assessed up to 80 months after the beginning of the study"
            }, 
            {
                "description": "The study will take into account all adverse events observed during and after drug administration, with a particular interest for:\nAny AE Any serious AE Any serious AE related to study treatment Any NCI-CTC grade 3 or 4 AE Any AE causing discontinuation of study treatment Any AE causing a dose reduction of study medication Any AE leading to death", 
                "measure": "Safety profile of each treatment sequence", 
                "safety_issue": "No", 
                "time_frame": "Assessed from study entry to 1 month after last study drug administration, assessed up to 80 months after the beginning of the study"
            }
        ], 
        "source": "Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)", 
        "sponsors": {
            "collaborator": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}